A Phase 2 Study of IPI-926 in Patients With Myelofibrosis.

Trial Profile

A Phase 2 Study of IPI-926 in Patients With Myelofibrosis.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Patidegib (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Biomarker; Therapeutic Use
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 22 Jun 2012 New source identified and integrated (2011-0445: M.D. Anderson Cancer Center).
    • 18 Jun 2012 Status changed from recruiting to discontinued, according to an Infinity Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top